跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
anti-IL-4/IL-13 antibody
首页
药物
anti-IL-4/IL-13 antibody
anti-IL-4/IL-13 antibody
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Anti-IL-4/anti-IL-13 bispecific antibody formulations
申请人: SANOFI SA
优先权: 2014
US
Methods for treating digitally identified IL-4/IL-13-related disorders by administering an anti-IL4R-alpha antibody
申请人: SANOFI BIOTECHNOLOGY
优先权: 2020
US
COMBINATION OF IL-4/IL-13 PATHWAY INHIBITORS AND PLASMA CELL ABLATION FOR TREATING ALLERGY
申请人: REGENERON PHARMA
优先权: 2019
CN
EP
US
WO
7 件公开
ANTI-IL-4Rα SINGLE-DOMAIN ANTIBODY, FUSION PROTEIN THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF
申请人: BIOTHEUS INC
优先权: 2024
CN
WO
2 件公开
Methods for treating active eosinophilic esophagitis
申请人: REGENERON PHARMA
优先权: 2018
US
METHODS FOR TREATING ACTIVE EOSINOPHILIC ESOPHAGITIS
申请人: REGENERON PHARMA
优先权: 2017
CN
EP
2 件公开
MASKED IL-2 FUSION PROTEINS
申请人: MEDICENNA THERAPEUTICS INC
优先权: 2024
WO
Anti-human interleukin-4 receptor alpha antibody and preparation method and application thereof
申请人: SHANGHAI MABGEEK BIOTECH CO LTD
优先权: 2020
US
3 件公开
药物
反馈